Eloxx Pharmaceuticals Announces First Patients Dosed In Phase 2B Exact Study Of Exaluren In Nonsense Mutation Alport Syndrome - ELOX News | RalliesEloxx Pharmaceuticals Announces First Patients Dosed In Phase 2B Exact Study Of Exaluren In Nonsense Mutation Alport Syndrome
E
ELOX• First patients dosed in Phase 2B study
- Eloxx Pharmaceuticals Inc. announced first patients were dosed in its Phase 2B Exact study of exaluren in nonsense mutation Alport syndrome.
- Topline data from the 16-week study is expected in mid-2027, with final readout by the end of 2027.
•
